BPC-157
A synthetic 15-amino-acid peptide derived from a sequence in human gastric juice, marketed for accelerated healing of tendon, ligament, muscle and gut tissue. Despite an enormous online following, there are essentially no controlled human trials — the entire evidence base is rodent studies and user anecdote. Sold only as a research chemical; not approved for human use anywhere.
01 Overview
BPC-157 (Body Protection Compound-157) is a partial sequence of a protein found in gastric juice. In rats it has repeatedly been reported to speed healing of transected tendons, damaged muscle, and colitis, and to protect the gut lining against NSAID injury. These preclinical findings are consistent across many papers, but the great majority originate from a small number of related research groups, and the peptide has never completed a published, peer-reviewed randomised controlled trial in humans.
What is claimed — rapid tendon/ligament repair, joint pain relief, gut healing, systemic anti-inflammatory effects — is almost entirely extrapolated from animal work and self-reported user experience. Because there is no human pharmacokinetic or safety dataset, dosing conventions are inherited from bodybuilding forums rather than clinical study. Buyers should treat it as an experimental compound of unknown human efficacy and unknown long-term safety.
02 Mechanism
Proposed to promote angiogenesis and fibroblast activity and to upregulate growth-factor and nitric-oxide pathways (including VEGFR2 and the FAK-paxillin pathway), accelerating tissue repair. Mechanistic claims derive from rodent and in-vitro work; the pathways operative in humans are unconfirmed.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Typical anecdotal | 250–500 mcg/day | SubQ | Common self-reported range, often split into two injections near the injury site. No clinical basis. |
| High anecdotal | 500–1000 mcg/day | SubQ | Used by some for acute injury; safety of higher doses is undocumented. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Accelerated soft-tissue healingFaster tendon, ligament and muscle repair shown repeatedly in rat models; not demonstrated in controlled human trials. | Marked in rodents | Preclinical | |
| Gut protection / anti-inflammatory effectProtects against NSAID-induced gastric lesions and reduces colitis severity in rodents. Human gut effects are anecdotal only. | Preclinical | ||
| Joint and injury pain reliefWidely reported by users for tendinopathy and joint pain; no trial evidence. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Injection-site reactionsRedness, transient stinging or bruising at the injection site. | Mild | Common with subcutaneous use | Anecdotal | |
| Unknown long-term safetyNo human toxicology, carcinogenicity or long-term safety data exists. Angiogenic activity raises a theoretical concern about promoting tumour vascularisation, unproven either way. | Moderate | Unquantified | Unconfirmed |
06 Commonly used with
What bpc-157 is combined with, and why. This is about intent rather than safety — the interactions table below covers what is dangerous. Nothing here is listed without what it costs.
| Compound | Frequency | Purpose & trade-off |
|---|---|---|
| Stacked compounds | ||
| TB-500thymosin beta-4 fragment | The classic healing pair — BPC-157 is run alongside TB-500 to combine local angiogenic/tissue-repair effects with TB-500's more systemic cell-migration and flexibility effects for soft-tissue and tendon injuries.Trade-off: Both rest almost entirely on animal data with essentially no controlled human trials, so you are stacking two unproven agents and doubling the unknown long-term and injection-site risk. | |
| IpamorelinGHRP | A GH secretagogue is sometimes added to raise systemic GH/IGF-1 and theoretically speed the connective-tissue repair BPC-157 is being used for.Trade-off: It adds GH-related side effects (water retention, carpal-tunnel-like symptoms, blunted insulin sensitivity) on top of an already speculative injury protocol with no evidence the two actually synergise in humans. | |
| Support & ancillaries | ||
| Collagen peptides + vitamin Coral, pre-rehab | Taken before loading/rehab to supply the substrate and cofactor for collagen synthesis that BPC-157 is meant to be accelerating.Trade-off: The oral collagen evidence is modest and it does nothing for BPC-157's own lack of human data — it is a cheap adjunct, not a fix for the core uncertainty. | |
| NSAIDibuprofen/naproxen) (as-needed | Used short-term for pain control during the acute phase while relying on BPC-157 for the actual repair.Trade-off: NSAIDs blunt the inflammatory signalling that early tendon and muscle healing depends on, so they can work against the very recovery goal the peptide is chasing. | |